Filing search / Centessa Pharmaceuticals plc / "Chronic"

424B5

CNTA Centessa Pharmaceuticals plc

13 Sep 24

Prospectus supplement for primary offering

4:02pm

of the maintenance of wakefulness test (MWT). Electroencephalogr Clin Neurophysiol 1997; 103:554-62. Narcolepsy is a chronic debilitating neurologic

424B5

CNTA Centessa Pharmaceuticals plc

11 Sep 24

Prospectus supplement for primary offering

4:40pm

. Narcolepsy is a chronic debilitating neurologic disorder that affects the brain’s ability to regulate the normal sleep-wake cycle. Narcolepsy

424B5

CNTA Centessa Pharmaceuticals plc

24 Apr 24

Prospectus supplement for primary offering

8:53pm

agonist for the treatment of NT1, NT2 and other sleep-wake disorders, including IH. Narcolepsy is a chronic debilitating neurologic disorder

424B5

8rulyuna4

23 Apr 24

Prospectus supplement for primary offering

5:16pm

8-K

EX-99.1

d18a s7u86f

11 Dec 23

Regulation FD Disclosure

7:05am

8-K

EX-99.1

kpdm9eiw2r b6lkn

12 Dec 22

Regulation FD Disclosure

6:37am

8-K

EX-99.2

0562ho ww

12 Dec 22

Regulation FD Disclosure

6:37am

10-K

sqhvvlefewc eaeq

30 Mar 22

Annual report

12:00am

8-K

EX-99.1

37ro68

15 Nov 21

Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates

7:11am